Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
New data with pasritamig plus docetaxel support a recent pivotal start.
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
But biomarker enrichment and toxicity remain key for FX-909.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
